MedTrace Logo

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

NCT00943592 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2014-02-27

Study results available
· View outcomes & findings →

Summary

This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leukemia, lymphoma and myeloma.

Conditions

  • Advanced Hematologic Malignancies
  • Leukemia
  • Preleukemia

Interventions

DRUG

Clofarabine

Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).

DRUG

Melphalan

Doses ranging from 100 to 140 mg/m2

DRUG

Campath

20mg/d x5

PROCEDURE

Stem Cell Transplant

Infusion of donor, bone marrow and auto.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Andrew Artz, MD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2011-04-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943592 on ClinicalTrials.gov